US FDA Recalibrates Office Of Generic Drugs
As Part Of Wider Structural Changes To CDER
As part of a wider overhaul of the FDA’s Center for Drug Evaluation and Research, the agency is reorganizing its Office of Generic Drugs, including adding a new Office of Safety and Clinical Evaluation within the OGD.
You may also be interested in...
Innovent Biologics has broadened its international reach by striking a licensing deal with PT Etana Biotechnologies in Indonesia for its Byvasda bevacizumab biosimilar.
Guidance on protecting participants in bioequivalence studies during the COVID-19 pandemic has been published by the FDA.
Teva has launched its generic version of NuvaRing in the US, adding a second rival generic to the market that already includes Amneal, as well as an authorized generic version from Prasco.